Table 1.
Patient disposition (N = 37)
| Status | Patients, n (%) |
|---|---|
| Enrolled until official study termination | 3 (8.1) |
| Discontinued before official study termination a | 34 (91.9) |
| Continuing leniolisib outside study b | 31 (83.8) |
| Discontinued leniolisib during study | 6 (16.2) |
| AE | 1 (2.7) |
| Death | 1 (2.7) |
| Lost to follow-up | 2 (5.4) |
| Subject/guardian decision | 2 (5.4) |
a
Patients in this category did not necessarily discontinue leniolisib.
b
Includes patients on commercial drug and through an early-access program.